Synact Pharma's Covid-19 disease trials cheaper than expected
Listed company Synact Pharma has moved a study from Europe to Brazil and significantly lowers the expected costs of the trial that tests the company's main candidate as a supplementary treatment for Covid-19 patients.
BY MIKKEL AABENHUS HEMMINGSEN & ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.